 NEW YORK, Sept. 21, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient-focused biopharmaceutical company, announced today that a Safety Review Committee SRC has reviewed the safety data from the first cohort of healthy subjects and recommended that the study proceed to dosing patients with mild to moderate atopic dermatitis, also known as eczema. 